SCHEMBL20158026

SCHEMBL20158026

C=Cc1ccc(Br)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.61
TUBB1 Q9H4B7 5/20 0.46
TUBB4A P04350 3/20 0.44
TUBB P07437 3/20 0.44
TUBA3C P0DPH7 3/20 0.44
TUBA1B P68363 3/20 0.44
TUBA4A P68366 3/20 0.44
TUBB4B P68371 3/20 0.44
TUBB3 Q13509 3/20 0.44
TUBB2A Q13885 3/20 0.44
TUBB8 Q3ZCM7 3/20 0.44
TUBA3E Q6PEY2 3/20 0.44
TUBA1A Q71U36 3/20 0.44
TUBA1C Q9BQE3 3/20 0.44
TUBB6 Q9BUF5 3/20 0.44
TUBB2B Q9BVA1 3/20 0.44
APP P05067 3/20 0.44
ALDH1A1 P00352 4/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096857 0.84 TUBB1 (0.59) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL30882817 0.83 TRPA1 (0.66) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL29130913 0.82 TUBB1 (0.47) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL29778007 0.81 TRPA1 (0.68) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL33786 0.81 TRPA1 (0.68) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL23714702 0.80 TUBB1 (0.49) TRPA1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL1159623 0.80 ALDH1A1 (0.68) TUBB1ALDH1A1TSHRMAPTTRIM24
SCHEMBL16957857 0.79 ALDH1A1 (0.44) TRPA1ALDH1A1TSHR
Methoxymethane SCHEMBL28668338 0.79 TRPA1 (0.66) TRPA1TUBB1TUBB4ATUBBTUBA3C
Ethylene SCHEMBL28209809 0.79 TRPA1 (0.66) TRPA1TUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597733-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2023-03-07 US disclosed
WO-2021078120-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2021-04-29 WO disclosed
US-20210115065-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2021-04-22 US disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597733-B2 Compounds and compositions for the treatment of parasitic diseases ABCB11, SQLE, FURIN TRPA1 2228/4885TUBB1 1192/4885TUBB4A 1402/4885
US-20210115065-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES ABCB11, SQLE, FURIN TRPA1 2228/4885TUBB1 1192/4885TUBB4A 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.